Correlation Between Blueprint Medicines and 4D Molecular

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Blueprint Medicines and 4D Molecular at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Blueprint Medicines and 4D Molecular into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Blueprint Medicines Corp and 4D Molecular Therapeutics, you can compare the effects of market volatilities on Blueprint Medicines and 4D Molecular and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Blueprint Medicines with a short position of 4D Molecular. Check out your portfolio center. Please also check ongoing floating volatility patterns of Blueprint Medicines and 4D Molecular.

Diversification Opportunities for Blueprint Medicines and 4D Molecular

-0.14
  Correlation Coefficient

Good diversification

The 3 months correlation between Blueprint and FDMT is -0.14. Overlapping area represents the amount of risk that can be diversified away by holding Blueprint Medicines Corp and 4D Molecular Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on 4D Molecular Therapeutics and Blueprint Medicines is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Blueprint Medicines Corp are associated (or correlated) with 4D Molecular. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of 4D Molecular Therapeutics has no effect on the direction of Blueprint Medicines i.e., Blueprint Medicines and 4D Molecular go up and down completely randomly.

Pair Corralation between Blueprint Medicines and 4D Molecular

Given the investment horizon of 90 days Blueprint Medicines Corp is expected to generate 0.42 times more return on investment than 4D Molecular. However, Blueprint Medicines Corp is 2.39 times less risky than 4D Molecular. It trades about -0.19 of its potential returns per unit of risk. 4D Molecular Therapeutics is currently generating about -0.13 per unit of risk. If you would invest  9,508  in Blueprint Medicines Corp on October 6, 2024 and sell it today you would lose (673.00) from holding Blueprint Medicines Corp or give up 7.08% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Blueprint Medicines Corp  vs.  4D Molecular Therapeutics

 Performance 
       Timeline  
Blueprint Medicines Corp 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Blueprint Medicines Corp has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound primary indicators, Blueprint Medicines is not utilizing all of its potentials. The recent stock price tumult, may contribute to shorter-term losses for the shareholders.
4D Molecular Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days 4D Molecular Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's primary indicators remain comparatively stable which may send shares a bit higher in February 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Blueprint Medicines and 4D Molecular Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Blueprint Medicines and 4D Molecular

The main advantage of trading using opposite Blueprint Medicines and 4D Molecular positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Blueprint Medicines position performs unexpectedly, 4D Molecular can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in 4D Molecular will offset losses from the drop in 4D Molecular's long position.
The idea behind Blueprint Medicines Corp and 4D Molecular Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.

Other Complementary Tools

Global Correlations
Find global opportunities by holding instruments from different markets
Stocks Directory
Find actively traded stocks across global markets
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm